Short-term withdrawal from imiglucerase: what can we learn from it?

Blood Cells Mol Dis. 2011 Jan 15;46(1):105-6. doi: 10.1016/j.bcmd.2010.05.003. Epub 2010 Jun 1.

Author

Carla E M Hollak¹

Affiliation

¹ Academic Medical Centre, F5-170, PO box 22660, 1100 DD Amsterdam, The Netherlands. c.e.hollak@amc.uva.nl

PMID: 20684887
DOI: 10.1016/j.bcmd.2010.05.003

No abstract available

MeSH terms

Enzyme Replacement Therapy*
Gaucher Disease / drug therapy*
Glucosylceramidase / administration & dosage
Glucosylceramidase / therapeutic use*
Humans
Patient Care Planning
Time Factors

Substances

Glucosylceramidase
imiglucerase